Assembly Bio reports 94% reduction in HSV-2 shedding with ABI-5366 350mg weekly in Phase 1b

ASSEMBLY BIOSCIENCES, INC.

94% reduction in HSV-2 shedding rate (p<0.01) for 350mg weekly dose vs placebo over 29-day evaluation.
98% reduction in high viral load shedding (p<0.05) and 94% reduction in genital lesion rate (p<0.01) with 350mg weekly.
ABI-5366 well-tolerated; majority of TEAEs Grade 1-2; no serious adverse events reported.
PK supports weekly and potential monthly dosing; Phase 2 preparation initiated; chronic tox studies complete.
Gilead has opt-in rights to the helicase-primase program; ABI-1179 and monthly cohort data expected fall 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.